# Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07389265/  
OnCo record `nct07389265` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of cetuximab, bevacizumab (glioblastoma use), fOLFOX (5-FU, leucovorin, oxaliplatin) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by University of Campania Luigi Vanvitelli, now recruiting.

## Summary

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT07389265 by University of Campania Luigi Vanvitelli, with a registry enrolment figure of 480 participants, started 2025-10-01 and due to reach its primary completion in 2030-10. Interventions recorded: Erbitux (Cetuximab); Bevacizumab; FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin); FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan). Conditions listed: Metastatic Colorectal Cancer (mCRC). Primary outcome: Overall Response Rate (ORR). Colorectal eligibility wording from the registry: "Histologically proven diagnosis of colorectal adenocarcinoma". Sites: Italy, Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CAPRI-3 GOIM
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07389265
- Phase: 3
- Setting: CAPRI-3 GOIM Study: Phase 3 Clinical Study to Evaluate the Use of Continuing Cetuximab Treatment Beyond First Line Progression in Molecular Selected Metastatic Colorectal Cancer Patients.
- Sponsor: University of Campania Luigi Vanvitelli
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT07389265: https://clinicaltrials.gov/study/NCT07389265

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07389265.json